Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review

Mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a low-frequency driver mutation in metastatic non-small cell lung cancer (NSCLC) (3%–4%) and is associated with a poor prognosis. With the advent of selective MET inhibitors such as capmatinib, tepotinib, and savolitinib,...

Full description

Bibliographic Details
Main Authors: Jiangfang Tian, Zhen Lin, Yueyun Chen, Yang Fu, Zhenyu Ding
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
neoadjuvant therapy
savolitinib
MET exon 14 skipping mutation (METex14)
NSCLC
case report
major pathological response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1006634/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1006634/full

Similar Items